Pilloxa
Digital Solutions for Medical Adherence and Patient Retention
The National Institute of Allergy and Infectious Diseases in the US has awarded a $36m contract to Tetraphase to develop TP-271, an antibiotic for respiratory disease.
National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $36m contract to develop Tetraphase’s antibiotic for respiratory disease, TP-271.
The NIAID award covers development, manufacturing, and clinical activities to position TP-271 for further development against certain biothreat agents, including Francisella tularensis and bacterial pathogens associated with community-acquired bacterial pneumonia (CABP).
The company said it will be working on this contract as a sub-contractor to New York, US-based independent not-for-profit scientific company CUBRC.
Tetraphase president and CEO Guy Macdonald said Tetraphase and CUBRC share NIAID’s commitment to addressing the global concerns of bioterrorism and antibiotic resistance.
Digital Solutions for Medical Adherence and Patient Retention
Software, Consulting and Workshops for Data Analysis and Model-Based Decision Support
ZUMEDU Secure Peer-to-Peer Video Conference Solutions for Clinical Researchers